Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia

Randomized Control Trial on Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia

To compare the efficacy and cost-effectiveness between purified CD34+ cells and peripheral blood mononuclear cells in treatment of critical limb ischemia

Inclusion Criteria:

• Rutherford scale of 4-5
• thromboangiitis obliterans, peripheral arterial disease, or arteritis caused by other etiologies, such as collagen diseases
• surgical or endovascular procedures are considered unlikely to have successful long-term revascularization, or have failed
• more than 4 weeks of critical limb ischemia
• if present, a non-healing ulcer after more than 4 weeks of optimal care by a wound care physician and a nurse

Exclusion Criteria:

• within 3 months of an acute myocardial infarction
• any contraindication for the administration of granulocyte colony stimulating factor (G-CSF)